Clinical trials: Birch Pollen Allergy
Allergy
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
- Trial name
- NCT00310466
- Testing
- Sublingual immunotherapy
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- ALK-Abelló A/S
Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy
SUBLIVAC® Birch PROBE Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in…
- Trial name
- NCT00932607
- Testing
- sublingual immunotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- HAL Allergy
Allergic Rhinitis
Efficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to Pollen
Study design: Randomized, controlled, double-blind, parallel, multicentre multinational clinical trial, to show superiority of an active therapy as compared to a control therapy on intermittent or persistent Allergic Rhinitis.
- Trial name
- NCT01478425
- Testing
- Lipidic Microemulsion, Saline
- Where
- 9 sites in Spain, Sweden
- Volunteers
- 110 people
- Sponsor
- Reig Jofre Group
Type I Hypersensitivity
Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Tree MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00107705
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with…
- Trial name
- ATIBAR (NCT02943720)
- Testing
- AllerT
- Where
- 36 sites in Denmark, Finland and 6 more
- Volunteers
- 421 people
- Sponsor
- Anergis
Birch Pollen Allergy
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
The objectives of this monocentric investigator initiated exploratory clinical trial is to optimize allergen delivery across the epidermal barrier.
- Trial name
- NCT01628484
- Testing
- prick lancet, Tape stripping, Microneedle
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Birch Pollen Allergy
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults.
- Trial name
- UPSIT (NCT07898800)
- Testing
- DM-101PX
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Desentum Oy
Allergic Rhinitis, Allergic Conjunctivitis
Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
Nasal allergen study in patients aged 60+ with or without current respiratory allergy
- Trial name
- AllergyAge (NCT06459219)
- Where
- Austria
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Sven Schneider, MD
Allergic Rhinitis Due to Pollen
Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen
Clinical efficacy and tolerability for allergen specific immunotherapy (AIT) with Itulazax (birch pollen extract tablet) is well established.
- Trial name
- NAC (NCT06085963)
- Testing
- ITULAZAX 12 SQ-Bet, Nacl
- Where
- Sweden
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and…
- Trial name
- YOBI (NCT05668390)
- Testing
- STALORAL® Birch 300 IR
- Where
- 62 sites in Austria, Bulgaria and 10 more
- Volunteers
- 553 people
- Sponsor
- Stallergenes Greer
Birch Pollen Induced Rhinitis/Rhinoconjunctivitis
SUBLIVAC FIX Birch Phase III Short-term Efficacy
The aim of this phase III study is to asses if SUBLIVAC FIX Birch is safe and effective in reducing birch allergy induced symptoms and birch allergy medication usage.
- Trial name
- NCT02231307
- Testing
- SUBLIVAC FIX Birch
- Where
- 40 sites in Belgium, Czechia and 3 more
- Volunteers
- 406 people
- Sponsor
- HAL Allergy
Birch Pollen Allergy
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
- Trial name
- NCT00266526
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
House Dust Mite Allergy, Birch Pollen Allergy
Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects
Skin prick test (SPT) is a first line diagnostic test to detect type I hypersensitivity in patients suspected of an inhalant allergy. A novel S.P.A.T.
- Trial name
- SPATprovocatio (NCT06803953)
- Testing
- Skin Prick Automated Test, Skin Prick Manual Test, Nasal Allergen Challenge
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hippocreates
Allergy
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
- Trial name
- NCT00410930
- Testing
- Subcutaneous immunotherapy - Recombinant birch pollen
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Stallergenes Greer
Birch Pollen Allergy
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults.
- Trial name
- NCT06037148
- Testing
- DM-101PX
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Desentum Oy
Allergic Rhinitis
Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen
Assessment of skin reactivity by skin prick tests to synthetic peptides derived from the major birch allergen bet v 1, in subjects allergic to birch pollen.
- Trial name
- NCT01719133
- Testing
- Histamine, AllerT1, AllerT2
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Anergis
Rhinitis, Allergic, Seasonal
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
This is first-in-human phase 1/2 clinical trial to evaluate the safety, systemic and local reactogenicity of GNR-127 at the first stage in sequential cohorts of patients with allergic rhinitis with sensitization to the birch…
- Trial name
- NCT07155499
- Testing
- GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- AO GENERIUM
Allergic Rhinitis, Food Allergy
Analysis of Immunological Reactions to Foods in Birch Pollen-Allergic Patients
A high number of birch pollen-allergic individuals develop hypersensitivity reactions to certain foods, e.g. apples. This food allergy is due to immunological cross-reactivity. Birch pollen-related foods contain proteins, e.g.
- Trial name
- NCT00787631
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Birch Pollen Allergy
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.
- Trial name
- NCT04266028
- Testing
- DM-101
- Where
- Finland
- Volunteers
- 27 people
- Sponsor
- Desentum Oy
Rhinitis, Allergic, Seasonal, Hay Fever
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
This study evaluates the effect of intramuscular injected methylprednisolone treating birch pollen induced rhinitis compared to placebo.
- Conditions
- Rhinitis, Allergic, Seasonal, Hay Fever, Pollen Allergy, Allergic Rhinitis
- Trial name
- NCT04622917
- Testing
- MethylPREDNISolone 40 Mg/mL Injectable Suspension, NaCl 9 MG/ML Injectable Solution
- Where
- Sweden
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet